Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
Real-time Quote. Real-time CHI-X - 10/18 11:30:00 am
8.15 EUR   +0.87%
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate, PXL065
AQ
08/26POXEL : Half-year results
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Poxel Announces Third Quarter and Nine Months 2018 Financial Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/18/2018 | 06:47am EDT

POXEL SA (Euronext POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its cash position and revenue for the third quarter and nine months ended September 30, 2018.

As of September 30, 2018, cash and cash equivalents were EUR 76.8 million (USD 88.8 million). The cash position reported reflects the DeuteRx upfront payment of EUR 6.8 million (USD 8 million) for the acquisition of PXL065 (DRX-065), a clinical-stage program for NASH, and additional programs, including deuterated drug candidates for metabolic, specialty and rare diseases. The companys cash runway extends into 2021 and includes the completion of clinical proof-of-concept studies for NASH for both PXL770 and PXL065.

Poxel reported revenues of EUR 17.5 million for the quarter ended September 30, 2018 and EUR 55.0 million for the nine months ended September 30, 2018 compared with no revenue during the same periods in 2017.

The revenue reflects a portion of the EUR 36 million upfront payment received from Sumitomo Dainippon Pharma relating to the strategic corporate partnership announced on October 30, 2017 and the USD 35 million (EUR 28 million) upfront payment associated with the corporate partnership announced with Roivant Sciences on February 12, 2018 net of Poxels financial contribution to Roivant. In addition, the revenue also reflects the Imeglimin Phase 3 program costs in Japan incurred during the first nine months of 2018 that were re-invoiced to Sumitomo Dainippon Pharma. Both the upfront payment from Sumitomo Dainippon Pharma and re-invoiced costs of the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program are recognized according to the percentage of completion for this program.

I am very pleased to report that during the third quarter we continued to make substantial progress for Imeglimin in Japan and all three pivotal Phase 3 TIMES trials are now fully enrolled with over 1,100 patients. We are on track for the data readout in 2019, beginning with the TIMES 1 efficacy study readout during the second quarter of 2019. We are continuing to work closely with our partner Sumitomo Dainippon Pharma in preparing for the Japanese New Drug Application submission in 2020, said Thomas Kuhn, CEO of Poxel. For the United States and Europe, we are working closely with Roivant Sciences and Metavant, a company formed by Roivant Sciences to develop innovative therapies for metabolic disorders, on progressing the Imeglimin clinical program, which is initially targeting patients with type 2 diabetes and moderate-to-severe chronic kidney disease (CKD stages 3b/4), and includes a dedicated clinical trial currently ongoing.

For our second program, PXL770, we have also continued to make substantial progress and completed the Phase 1 multiple ascending dose study. We believe that PXL770 has the potential to treat liver diseases, such as NASH, and could have the potential to treat additional metabolic diseases. We are currently preparing for the initiation of a Phase 2a proof-of-concept program in nonalcoholic fatty liver disease (NAFLD) patients who likely have NASH, added Thomas Kuhn. With our recent acquisition of DeuteRxs drug candidate, PXL065 (formerly DRX-065), we are rapidly expanding our presence in NASH and are one of only a few biotech companies with two clinical programs in development in this therapeutic area. The underlying pathophysiological mechanisms that contribute to the development and progression of NAFLD and NASH are highly complex and support the need for the development of novel therapies acting on different targets. Both of our programs, which we plan on advancing into Phase 2 in 2019, have the potential to be developed as a monotherapy or in combination together or with other agents.

(c) 2018 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
POXEL 2.48% 8.28 Real-time Quote.58.74%
SUMITOMO CHEMICAL COMPANY, LIMITED 0.00% 507 End-of-day quote.-0.78%
SUMITOMO DAINIPPON PHARMA CO., LTD. -0.28% 1812 End-of-day quote.-46.63%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on POXEL
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate..
AQ
08/26POXEL : Half-year results
CO
08/06POXEL : Initiates Pharmacokinetic Pharmacodynamic Study as part of the Phase 2a ..
AQ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15POXEL : 2nd quarter earnings
CO
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
06/25POXEL : and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results ..
PU
04/10Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Im..
AQ
04/08POXEL : Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Tr..
PU
More news
Financials (EUR)
Sales 2019 40,0 M
EBIT 2019 -17,5 M
Net income 2019 -15,1 M
Finance 2019 33,4 M
Yield 2019 -
P/E ratio 2019 -13,6x
P/E ratio 2020 -5,79x
EV / Sales2019 4,39x
EV / Sales2020 7,44x
Capitalization 209 M
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,13  €
Last Close Price 8,08  €
Spread / Highest target 110%
Spread / Average Target 87,3%
Spread / Lowest Target 69,6%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Anne Renevot Chief Financial Officer
Sophie Hallakou-Bozec Senior Vice Chairman-Research & Development
Christophe Arbet-Engels Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
POXEL58.74%232
GILEAD SCIENCES4.28%82 611
VERTEX PHARMACEUTICALS6.26%45 680
REGENERON PHARMACEUTICALS-19.26%32 998
WUXI APPTEC CO., LTD.68.13%20 570
GENMAB32.08%13 649